CN110536963A - B细胞工程改造 - Google Patents

B细胞工程改造 Download PDF

Info

Publication number
CN110536963A
CN110536963A CN201880021264.1A CN201880021264A CN110536963A CN 110536963 A CN110536963 A CN 110536963A CN 201880021264 A CN201880021264 A CN 201880021264A CN 110536963 A CN110536963 A CN 110536963A
Authority
CN
China
Prior art keywords
cell
cells
protein
antibody
genetic modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880021264.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·阿莫拉
M·C·霍尔姆斯
B·E·赖利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangamo Therapeutics Inc
Original Assignee
Sangamo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Therapeutics Inc filed Critical Sangamo Therapeutics Inc
Publication of CN110536963A publication Critical patent/CN110536963A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880021264.1A 2017-01-26 2018-01-25 B细胞工程改造 Pending CN110536963A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762450917P 2017-01-26 2017-01-26
US62/450,917 2017-01-26
PCT/US2018/015180 WO2018140573A1 (en) 2017-01-26 2018-01-25 B-cell engineering

Publications (1)

Publication Number Publication Date
CN110536963A true CN110536963A (zh) 2019-12-03

Family

ID=62979713

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880021264.1A Pending CN110536963A (zh) 2017-01-26 2018-01-25 B细胞工程改造

Country Status (11)

Country Link
US (1) US20190352614A1 (cg-RX-API-DMAC7.html)
EP (1) EP3573464A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020505044A (cg-RX-API-DMAC7.html)
KR (1) KR20190111063A (cg-RX-API-DMAC7.html)
CN (1) CN110536963A (cg-RX-API-DMAC7.html)
AU (1) AU2018212652B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019015355A2 (cg-RX-API-DMAC7.html)
CA (1) CA3051113A1 (cg-RX-API-DMAC7.html)
IL (1) IL268110B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019008844A (cg-RX-API-DMAC7.html)
WO (1) WO2018140573A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
IL268110B2 (en) * 2017-01-26 2024-01-01 Sangamo Therapeutics Inc B-cell engineering
EP3595681A4 (en) * 2017-03-16 2020-12-16 Seattle Children's Hospital (DBA Seattle Children's Research Institute) TRANSPLANT CELL-BASED IMMUNOTHERAPY FOR LONG-PERIOD ADMINISTRATION OF THERAPEUTIC PROTEIN
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス,インコーポレーテッド 第ix因子を発現するための組成物及び方法
JP7656830B2 (ja) 2019-11-01 2025-04-04 京都府公立大学法人 B細胞抗体受容体、及びその利用
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
WO2023192936A2 (en) * 2022-03-30 2023-10-05 Fred Hutchinson Cancer Center Systems and methods to produce b cells that express selected antibodies and gene products
WO2024151683A2 (en) * 2023-01-09 2024-07-18 Walking Fish Therapeutics, Inc. HUMAN B CELL ENGINEERED TO EXPRESS IgA AND IgM ANTIBODIES FOR THERAPEUTIC USE
WO2024196669A2 (en) * 2023-03-17 2024-09-26 Walking Fish Therapeutics, Inc. Methods for in vivo editing of b cells
WO2024220447A2 (en) * 2023-04-17 2024-10-24 Be Biopharma, Inc. Engineered cell preparations for treatment of niemann pick b disease
WO2026085108A2 (en) * 2024-10-14 2026-04-23 Immusoft Corporation B cell compositions and methods of use

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246452A1 (en) * 2003-03-28 2006-11-02 Gonda Thomas J Method for identifying nucleic acid molecules associated with angiogenesis
US20110287532A1 (en) * 2004-09-22 2011-11-24 St. Jude Children's Research Hospital Expression of factor ix in gene therapy vectors
EP2419511A1 (en) * 2009-04-09 2012-02-22 Sangamo BioSciences, Inc. Targeted integration into stem cells
US20160022737A1 (en) * 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
CN105683376A (zh) * 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
WO2016161446A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
US20170016027A1 (en) * 2015-07-13 2017-01-19 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CN106795488A (zh) * 2014-09-16 2017-05-31 桑格摩治疗股份有限公司 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
WO2018140573A1 (en) * 2017-01-26 2018-08-02 Sangamo Therapeutics, Inc. B-cell engineering
US20190136261A1 (en) * 2017-11-09 2019-05-09 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible sh2-containing protein (cish) gene
CN110944660A (zh) * 2017-04-10 2020-03-31 伊玛提克斯生物技术有限公司 用于白血病和其他癌症免疫治疗的肽和肽组合物
CN110997913A (zh) * 2017-06-16 2020-04-10 桑格摩生物治疗股份有限公司 T细胞和/或hla受体的靶向破坏
CN111194349A (zh) * 2017-08-08 2020-05-22 桑格摩生物治疗股份有限公司 嵌合抗原受体介导的细胞靶向
AU2019216269A1 (en) * 2018-01-30 2020-05-28 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
WO2020112860A1 (en) * 2018-11-30 2020-06-04 Intima Bioscience, Inc. Methods of identifying immunomodulatory genes
CN112639102A (zh) * 2018-08-29 2021-04-09 南京传奇生物科技有限公司 抗间皮素嵌合抗原受体(car)构建体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4177336A1 (en) * 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
EP3402533B1 (en) * 2016-01-15 2021-08-04 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246452A1 (en) * 2003-03-28 2006-11-02 Gonda Thomas J Method for identifying nucleic acid molecules associated with angiogenesis
US20110287532A1 (en) * 2004-09-22 2011-11-24 St. Jude Children's Research Hospital Expression of factor ix in gene therapy vectors
EP2419511A1 (en) * 2009-04-09 2012-02-22 Sangamo BioSciences, Inc. Targeted integration into stem cells
CN105683376A (zh) * 2013-05-15 2016-06-15 桑格摩生物科学股份有限公司 用于治疗遗传病状的方法和组合物
US20160022737A1 (en) * 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
CN106795488A (zh) * 2014-09-16 2017-05-31 桑格摩治疗股份有限公司 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
WO2016161446A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
US20170016027A1 (en) * 2015-07-13 2017-01-19 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CN108024544A (zh) * 2015-07-13 2018-05-11 桑格摩生物治疗股份有限公司 用于核酸酶介导的基因组工程化的递送方法及组合物
WO2018140573A1 (en) * 2017-01-26 2018-08-02 Sangamo Therapeutics, Inc. B-cell engineering
US20190352614A1 (en) * 2017-01-26 2019-11-21 Sangamo Therapeutics, Inc. B-cell engineering
EP3573464A1 (en) * 2017-01-26 2019-12-04 Sangamo Therapeutics, Inc. B-cell engineering
CN110944660A (zh) * 2017-04-10 2020-03-31 伊玛提克斯生物技术有限公司 用于白血病和其他癌症免疫治疗的肽和肽组合物
CN110997913A (zh) * 2017-06-16 2020-04-10 桑格摩生物治疗股份有限公司 T细胞和/或hla受体的靶向破坏
CN111194349A (zh) * 2017-08-08 2020-05-22 桑格摩生物治疗股份有限公司 嵌合抗原受体介导的细胞靶向
US20190136261A1 (en) * 2017-11-09 2019-05-09 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible sh2-containing protein (cish) gene
CN111565730A (zh) * 2017-11-09 2020-08-21 桑格摩生物治疗股份有限公司 细胞因子诱导型含sh2蛋白(cish)基因的遗传修饰
AU2019216269A1 (en) * 2018-01-30 2020-05-28 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
CN112639102A (zh) * 2018-08-29 2021-04-09 南京传奇生物科技有限公司 抗间皮素嵌合抗原受体(car)构建体及其用途
WO2020112860A1 (en) * 2018-11-30 2020-06-04 Intima Bioscience, Inc. Methods of identifying immunomodulatory genes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAYONG SHIM等: "Therapeutic gene editing: delivery and regulatory perspectives", 《ACTA PHARMACOLOGICA SINICA》 *
YU ZHANG等: "Regulatory B cells in anti-tumor immunity", 《INTERNATIONAL IMMUNOLOGY》 *
李国玲等: "动物基因组定点整合转基因技术研究进展", 《遗传》 *
陈一飞等: "基因修饰细胞治疗产品的非临床研究关注点讨论", 《中国医药工业杂志》 *

Also Published As

Publication number Publication date
EP3573464A4 (en) 2020-12-30
IL268110B2 (en) 2024-01-01
AU2018212652B2 (en) 2024-03-28
CA3051113A1 (en) 2018-08-02
IL268110A (en) 2019-09-26
EP3573464A1 (en) 2019-12-04
MX2019008844A (es) 2019-09-10
JP2022191524A (ja) 2022-12-27
RU2019126606A (ru) 2021-02-26
IL268110B1 (en) 2023-09-01
JP2020505044A (ja) 2020-02-20
KR20190111063A (ko) 2019-10-01
WO2018140573A1 (en) 2018-08-02
BR112019015355A2 (pt) 2020-05-19
US20190352614A1 (en) 2019-11-21
RU2019126606A3 (cg-RX-API-DMAC7.html) 2021-06-11
AU2018212652A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
AU2018212652B2 (en) B-cell engineering
JP7348160B2 (ja) ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物
Lim et al. Treatment of a mouse model of ALS by in vivo base editing
JP7324249B2 (ja) 肝臓特異的コンストラクト、第viii因子発現カセット、およびその使用の方法
Pickar-Oliver et al. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy
Gaj et al. Genome engineering using adeno-associated virus: basic and clinical research applications
EP3080143B1 (en) Methods and compositions for treating hemophilia
JP2018533966A (ja) 免疫を工学操作するための方法および組成物
JP7432581B2 (ja) ムコ多糖症ii型の処置のための方法
CN120981573A (zh) 用于进行表观遗传修饰的组合物和方法
RU2783116C2 (ru) Модификация b-клеток
RU2774874C2 (ru) Печень-специфичные конструкции, экспрессионные кассеты фактора viii и способы их применения
HK1226756B (en) Methods and compositions for treating hemophilia
HK1225754B (en) Methods and compositions for genome engineering
HK40020799B (en) Delivery methods and compositions for nuclease-mediated genome engineering

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191203

WD01 Invention patent application deemed withdrawn after publication